{
    "clinical_study": {
        "@rank": "70762", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate lofexidine for opiate withdrawal."
        }, 
        "brief_title": "Lofexidine for Opiate Withdrawal - 1", 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment\n      seeking individuals randomized to 2 medication groups: lofexidine and placebo to be\n      conducted in inpatient units at 3 treatment sites."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male or female as least 18 yrs of age & above with a current dependence on heroin,\n        morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent\n        and signed informed consent; females using appropriate birth control method.\n\n        Exclusion Criteria:\n\n        Additional criteria available during screening at the site"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "66", 
        "firstreceived_date": "April 5, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": [
                "NCT00007566", 
                "NCT00024713"
            ], 
            "nct_id": "NCT00032942", 
            "org_study_id": "NIDA-CSP-1020-1"
        }, 
        "intervention": {
            "intervention_name": "Lofexidine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lofexidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 21, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10023"
                    }, 
                    "name": "Columbia University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Philadelphia Veterans Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal", 
        "overall_official": {
            "affiliation": "National Institute on Drug Abuse (NIDA)", 
            "last_name": "Ann Montgomery, R.N.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Opiate withdrawal symptoms"
            }, 
            {
                "measure": "Potential Abuse Liability"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032942"
        }, 
        "responsible_party": {
            "name_title": "Ann Montgomery", 
            "organization": "National Institute on Drug about"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "Britannia Pharmaceuticals Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2008"
    }, 
    "geocoordinates": {
        "Columbia University": "40.714 -74.006", 
        "Philadelphia Veterans Medical Center": "39.952 -75.164", 
        "UCLA Medical Center": "34.052 -118.244"
    }
}